autologous peripheral blood lymphocytes cotransduced with retroviral vectors encoding inducible IL-12 and anti-NY-ESO-1 TCR
Term · Oncology and biomedicine · MLC-T-ONC-011748
Human autologous peripheral blood lymphocytes (PBLs) transduced with two retroviral vectors, one encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1 and a second that encodes an inducible single chain form of interleukin-12 (IL-12) driven by a nuclear factor of activated T cells (NFAT)-responsive promoter, with potential immunomodulating and antineoplastic activities. Following isolation of lymphocytes, retroviral vector transduction, and expansion of the cells ex vivo, the inducible IL-12/anti-NY-ESO-1 TCR-expressing autologous PBLs are re-administered into the patient by intravenous injection. As the transduced PBLs traverse the patient's circulation, they can bind to NY-ESO-1-overexpressing tumor cells. This binding activates the TCR signaling pathway in the transduced PBLs, which promotes NFAT-dependent gene transcription and induces expression of the cotransduced IL-12. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death for the NY-ESO-1-overexpressing tumor cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. NFAT, a family of transcription factors involved in immune responses, is activated by calcium signaling, which can occur downstream of TCR activation. Use of a retroviral vector to express an inducible IL-12 may remove the requirement for concomitant administration of interleukin-2 (IL-2) as is the case for conventional cell transfer immunotherapies.
| Identifier | MLC-T-ONC-011748 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | IL-12 plus anti-ESO-1 TCR PBL; inducible IL-12/anti-NY-ESO-1 TCR-expressing autologous PBL; inducible IL-12/anti-NY-ESO-1 TCR-expressing autologous peripheral blood lymphocytes; autologous PBL cotransduced with retroviral vectors encoding inducible IL-12 and anti-NY-ESO-1 TCR; IL-12/anti-NY-ESO-1 TCR-expressing autologous peripheral blood lymphocytes; IL-12/Anti-NY-ESO-1 TCR-expressing autologous PBL; autologous lymphocytes cotransduced with genes encoding IL-12 and anti-NY-ESO-1 TCR |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011748",
"term": "autologous peripheral blood lymphocytes cotransduced with retroviral vectors encoding inducible IL-12 and anti-NY-ESO-1 TCR",
"field": "Oncology and biomedicine",
"definition": "Human autologous peripheral blood lymphocytes (PBLs) transduced with two retroviral vectors, one encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1 and a second that encodes an inducible single chain form of interleukin-12 (IL-12) driven by a nuclear factor of activated T cells (NFAT)-responsive promoter, with potential immunomodulating and antineoplastic activities. Following isolation of lymphocytes, retroviral vector transduction, and expansion of the cells ex vivo, the inducible IL-12/anti-NY-ESO-1 TCR-expressing autologous PBLs are re-administered into the patient by intravenous injection. As the transduced PBLs traverse the patient's circulation, they can bind to NY-ESO-1-overexpressing tumor cells. This binding activates the TCR signaling pathway in the transduced PBLs, which promotes NFAT-dependent gene transcription and induces expression of the cotransduced IL-12. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death for the NY-ESO-1-overexpressing tumor cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. NFAT, a family of transcription factors involved in immune responses, is activated by calcium signaling, which can occur downstream of TCR activation. Use of a retroviral vector to express an inducible IL-12 may remove the requirement for concomitant administration of interleukin-2 (IL-2) as is the case for conventional cell transfer immunotherapies.",
"synonyms": [
"IL-12 plus anti-ESO-1 TCR PBL",
"inducible IL-12/anti-NY-ESO-1 TCR-expressing autologous PBL",
"inducible IL-12/anti-NY-ESO-1 TCR-expressing autologous peripheral blood lymphocytes",
"autologous PBL cotransduced with retroviral vectors encoding inducible IL-12 and anti-NY-ESO-1 TCR",
"IL-12/anti-NY-ESO-1 TCR-expressing autologous peripheral blood lymphocytes",
"IL-12/Anti-NY-ESO-1 TCR-expressing autologous PBL",
"autologous lymphocytes cotransduced with genes encoding IL-12 and anti-NY-ESO-1 TCR"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-peripheral-blood-lymphocytes-cotransduced-with-retroviral-vectors-il/"
}
Record 3,084 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.